Valneva SE (VALN) Current Deferred Revenue (2019 - 2026)
Valneva SE (VALN) posted Current Deferred Revenue of $499908.4 for Q1 2026, down 0.59% sequentially from $502866.8 in Q4 2025, and down 87.33% YoY from $3.9 million in Q1 2025.
Valneva SE (VALN) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Valneva SE has reported Current Deferred Revenue for 8 years, with the latest figure at $499908.4 in Q1 2026.
- Quarterly Current Deferred Revenue fell 87.33% year-over-year to $499908.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499908.4 (down 87.33% YoY) and the FY2025 annual result came in at $502866.8, down 84.56% from the prior year.
- Current Deferred Revenue eased to $499908.4 in Q1 2026 per VALN's latest filing, from $502866.8 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $137.5 million in Q1 2022 and troughed at $361095.1 in Q2 2025.
- A 5-year average of $20.7 million and a median of $5.7 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue jumped 108.6% in 2023, then slumped 93.67% in 2025.
- Over 5 years, Current Deferred Revenue stood at $9.6 million in 2022, then sank by 36.16% to $6.1 million in 2023, then slumped by 47.53% to $3.2 million in 2024, then tumbled by 84.37% to $502866.8 in 2025, then dropped by 0.59% to $499908.4 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $499908.4, $502866.8, and $494510.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 581,180.93 |
| Mar 31, 2026 | 499,908.39 |
| Dec 31, 2025 | 502,866.80 |
| Sep 30, 2025 | 494,510.30 |
| Jun 30, 2025 | 361,095.14 |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 5.71 Mn |
| Mar 31, 2024 | 5.75 Mn |
| Dec 31, 2023 | 6.13 Mn |
| Sep 30, 2023 | 14.53 Mn |
| Jun 30, 2023 | 12.61 Mn |
| Mar 31, 2023 | 9.83 Mn |
| Dec 31, 2022 | 9.60 Mn |
| Sep 30, 2022 | 6.96 Mn |
| Jun 30, 2022 | 133.19 Mn |
| Mar 31, 2022 | 137.46 Mn |
| Dec 31, 2021 | 147.30 Mn |
| Dec 31, 2020 | 106.87 Mn |